Silk Road Medical
Develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies.
Launch date
Employees
Market cap
€1.0b
Enterprise valuation
€927m (Public information from Sep 2024)
Share price
$27.49 SILK
Sunnyvale California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 75.2m | 101m | 139m | 177m | 199m | 220m | 243m |
% growth | 19 % | 35 % | 37 % | 28 % | 13 % | 11 % | 10 % |
EBITDA | (41.8m) | (47.3m) | (49.7m) | (45.1m) | (14.4m) | (7.0m) | 1.3m |
% EBITDA margin | (56 %) | (47 %) | (36 %) | (25 %) | (7 %) | (3 %) | 1 % |
Profit | (47.4m) | (49.8m) | (55.0m) | (55.7m) | (55.1m) | (54.3m) | (50.8m) |
% profit margin | (63 %) | (49 %) | (40 %) | (31 %) | (28 %) | (25 %) | (21 %) |
EV / revenue | 28.1x | 14.0x | 13.5x | 2.1x | 5.5x | 4.8x | 4.3x |
EV / EBITDA | -50.7x | -30.1x | -37.8x | -8.3x | -75.7x | -152.5x | 836.8x |
R&D budget | 21.3m | 27.1m | 36.4m | 41.3m | - | - | - |
R&D % of revenue | 28 % | 27 % | 26 % | 23 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
$3.4m | Series A | ||
$8.2m | Series B | ||
$13.0m | Series B | ||
N/A | $17.0m | Series B | |
N/A | $15.0m | Late VC | |
$57.0m | Late VC | ||
$47.0m | Series C | ||
N/A | N/A | IPO | |
$50.0m | Debt | ||
* | $250m | Post IPO Debt | |
* | N/A | $100m | Post IPO Equity |
* | $1.2b Valuation: $1.2b | Acquisition | |
Total Funding | €146m |
Related Content
Recent News about Silk Road Medical
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.